The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.

The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.